1. Novel Tracers and Radionuclides in PET Imaging
   Christian Mason et al, 2021, Radiologic Clinics of North America CrossRef
2. PARP-1 selectively impairsKRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma
   Friederike L Keggenhoff et al, 2024, Gut CrossRef
3. Positive Helicobacter pylori status is associated with better overall survival for gastric cancer patients: evidence from case-cohort studies
   Xuqian Fang et al, 2017, Oncotarget CrossRef
4. NAD+Metabolism in Aging and Cancer
   Tyler G. Demarest et al, 2019, Annual Review of Cancer Biology CrossRef
5. An assessment of poly (ADP‐ribose) polymerase‐1 role in normal and cancer cells
   Manoj Kumar et al, 2020, BioFactors CrossRef
6. Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
   Abdullah Alhusaini et al, 2021, Biomedicines CrossRef
7. Combining PARP and DNA-PK Inhibitors With Irradiation Inhibits HPV-Negative Head and Neck Cancer Squamous Carcinoma Growth
   Ling Zeng et al, 2020, Frontiers in Genetics CrossRef
8. A review of poly(ADP-ribose)polymerase-1 (PARP1) role and its inhibitors bearing pyrazole or indazole core for cancer therapy
   Inês M. Bastos et al, 2024, Biochemical Pharmacology CrossRef
9. An electrostatic force-independent dephosphorylation-driven chemiluminescent biosensor for sensitive and rapid detection of poly(ADP-ribose) polymerase-1 in human breast tissues
   Ming-hao Liu et al, 2023, Chemical Engineering Journal CrossRef
10. Roles of DNMT3B and PARP1 Genes Expression in Cytogenetically Normal Acute Myeloid Leukemia
    Hager A Mahmoud et al, 2024, Clinical Medicine Insights: Oncology CrossRef
11. Leveraging PARP-1/2 to Target Distant Metastasis
    Mallory I. Frederick et al, 2024, International Journal of Molecular Sciences CrossRef
12. High Poly(ADP-Ribose) Polymerase Expression Does Relate to Poor Survival in Solid Cancers: A Systematic Review and Meta-Analysis
    Nishant Thakur et al, 2021, Cancers CrossRef
13. Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1
    Hazna Noor Meidinna et al, 2022, Frontiers in Cell and Developmental Biology CrossRef
14. Exploring the Potential Mechanism of Action of Ursolic Acid against Gastric Cancer and COVID-19 using Network Pharmacology and Bioinformatics Analysis
    Zhiyao Liu et al, 2023, Current Pharmaceutical Design CrossRef
15. In vitro selective cytotoxicity of the dietary chalcone cardamonin (CD) on melanoma compared to healthy cells is mediated by apoptosis
    Lena Berning et al, 2019, PLOS ONE CrossRef
16. Pinus kesiya Royle ex Gordon induces apoptotic cell death in hepatocellular carcinoma HepG2 cell via intrinsic pathway by PARP and Topoisomerase I suppression
    Piman Pocasap et al, 2021, Biomedicine & Pharmacotherapy CrossRef
17. Parp1 as a Prognostic Biomarker for Human Cancers: A Meta-Analysis
    Yan-Hua Huang et al, 2021, Biomarkers in Medicine CrossRef
18. Identification of Potential Poly (ADP-Ribose) Polymerase-1 Inhibitors Derived from Rauwolfia serpentina: Possible Implication in Cancer Therapy
    Adel M. Abuzenadah et al, 2022, Evidence-Based Complementary and Alternative Medicine CrossRef
19. Regorefenib induces extrinsic/intrinsic apoptosis and inhibits MAPK/NF‐κB‐modulated tumor progression in bladder cancer in vitro and in vivo
    Chih‐Hung Chiang et al, 2019, Environmental Toxicology CrossRef
20. Studies on the mechanism of local and extra-intestinal tissue manifestations in AOM-DSS-induced carcinogenesis in BALB/c mice: role of PARP-1, NLRP3, and autophagy
    Shivani Singla et al, 2024, Naunyn-Schmiedeberg's Archives of Pharmacology CrossRef
21. Upregulation of PARG in prostate cancer cells suppresses their malignant behavior and downregulates tumor-promoting genes
    Yaroslava Karpova et al, 2022, Biomedicine & Pharmacotherapy CrossRef
22. Overexpression of CLC-3 is regulated by XRCC5 and is a poor prognostic biomarker for gastric cancer
    Zhuoyu Gu et al, 2018, Journal of Hematology & Oncology CrossRef
23. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis
    Amilcar Barreta et al, 2019, Human Pathology CrossRef
24. PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes
    Nanami Gotoh et al, 2020, European Journal of Haematology CrossRef
25. The Prognostic Values of PARP-1 Expression in Uveal Melanoma
    Malgorzata Gajdzis et al, 2021, Cells CrossRef
26. Disrupting Poly(ADP-ribosyl)ating Pathway Creates Premalignant Conditions in Mammalian Liver
    Yaroslava Karpova et al, 2023, International Journal of Molecular Sciences CrossRef
27. PARP1 rs1136410 C/C genotype associated with an increased risk of esophageal cancer in smokers
    Rongmiao Zhou et al, 2021, Molecular Biology Reports CrossRef
28. Mutual regulation of TGFβ-induced oncogenic EMT, cell cycle progression and the DDR
    Harald Schuhwerk et al, 2023, Seminars in Cancer Biology CrossRef
29. Regulation of Biomolecular Condensates by Poly(ADP-ribose)
    Kevin Rhine et al, 2023, Chemical Reviews CrossRef
30. Therapeutic Targeting of Poly(ADP‐Ribose) Polymerase‐1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities
    Jyotika Rajawat et al, 2017, Medicinal Research Reviews CrossRef
31. PARP5B is required for nonhomologous end joining during tumorigenesis in vivo
    Jianchun Wu et al, 2022, Molecular Carcinogenesis CrossRef
32. PARP-1Overexpression as an Independent Prognostic Factor in Adult Non-M3 Acute Myeloid Leukemia
    Hossein Pashaiefar et al, 2018, Genetic Testing and Molecular Biomarkers CrossRef
33. PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment
    Sarah Johnson et al, 2022, BMC Cancer CrossRef
34. PARP-1 promotes tumor recurrence after warm ischemic liver graft transplantation via neutrophil recruitment and polarization
    Shuai Wang et al, 2017, Oncotarget CrossRef
35. Poly (Adp-Ribose) Polymerase-1 (PARP-1) Is a Good Prognostic Marker for Pancreatic/Periampullary Cancers
    Kwangil Yim et al, 2024, Pancreas CrossRef
36. Poly(ADP-ribose) polymerase1 (PARP1) and PARP inhibitors: New frontiers in cervical cancer
    Jyotika Rajawat et al, 2024, Biochemical and Biophysical Research Communications CrossRef
37. Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach
    Samuele Lodovichi et al, 2020, International Journal of Molecular Sciences CrossRef
38. DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment
    Takayuki Saitoh et al, 2021, Cancers CrossRef
39. Oxidative Stress Markers Are Associated with a Poor Prognosis in Patients with Pancreatic Cancer
    Miguel A. Ortega et al, 2022, Antioxidants CrossRef
40. Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases
    Simonetta Pazzaglia et al, 2019, Cells CrossRef
41. Immunohistochemical expression of poly(ADP-ribose) polymerase 1 and androgen receptors in triple-negative breast cancer
    Marwa E. Shabana et al, 2021, Egyptian Journal of Pathology CrossRef
42. Exploring homologous recombination repair and base excision repair pathway genes for possible diagnostic markers in hematologic malignancies
    Sumaira Fida Abbasi et al, 2023, Molecular Genetics and Genomics CrossRef
43. Pleiotropic role of PARP1: an overview
    Vikas Kumar et al, 2022, 3 Biotech CrossRef
44. Precision medicine in gastric cancer
    Patrizia Bonelli et al, 2019, World Journal of Gastrointestinal Oncology CrossRef
45. Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis
    Zhifang Jia et al, 2022, BMC Cancer CrossRef